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Abstract (249)
Background: It is suggested that airway fungi, in particular Aspergillus may impinge on clinical 
phenotype in asthma. Indeed the term severe asthma with fungal sensitisation (SAFS) has been 
coined. We aimed to ascertain whether the presence of fungi, in particular Aspergillus fumigatus, 
in the airway correlated with asthma severity and control. Furthermore, we aimed to determine if 
traditional markers of Aspergillus sensitisation related to the presence of Aspergillus within the 
airway.
Methods: Sixty-nine patients characterised by asthma severity (GINA) and level of control (ACQ-
7) underwent bronchoscopy and bronchoalveolar lavage (BAL). Serum was assessed for A. 
fumigatus specific IgE and total IgE. Galactomannan and relevant cytokine levels were assessed in 
serum, plasma and BAL. BAL was analysed for the presence of A. fumigatus. 
Results: In BAL, fungi were visible by microscopy in 70% and present by qPCR in 86% of 
patients, while A. fumigatus was detectable by qPCR in 46%. Plasma and BAL IL-4, IL-6, IL-10, 
IL-13 and TNF-α correlated with BAL fungal presence, while plasma IL-17 correlated with BAL 
fungal presence. Aspergillus positive BAL correlated with increased plasma and BAL IL-6 and 
BAL IL-13. There was no relationship between fungal airway presence and steroid dose, asthma 
severity or control. The presence of Aspergillus within the airway did not relate to serum IgE 
positivity for Aspergillus.
Conclusions: Fungi were present in a large proportion of our asthmatic patients’ airways, but their 
presence was not predicted by traditional markers of sensitisation, nor did it appear to be related to 
measures of disease severity or control.
Keywords: Allergy, Aspergillus fumigatus, Asthma, Bronchoscopy, Fungi 
Introduction 
The term severe asthma groups patients with varying pathophysiological and phenotypic 
characteristics1. Studies have suggested roles for fungi in severe asthma and the term severe 
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on demonstrating sensitisation to fungus in the absence of allergic bronchopulmonary aspergillosis 
(ABPA)2. Therapies aimed at fungal elimination have afforded mixed results3,4. 
The respiratory tract is constantly exposed to hyphal fragments, fungal spores and yeasts5-7. 
Thermotolerant fungi, including Candida, Aspergillus and Penicillium are sources of allergens, 
commensals and opportunistic pathogens and can colonise airways with potential clinical 
ramifications5.
Aspergillus fumigatus, a ubiquitous fungus can elicit a destructive response in a susceptible host8. 
Due to the spherical shape of A. fumigatus conidia, typically 2.0-3.0µm in diameter, the conidia 
can evade mucociliary clearance and reach the lower airways9. Pathogen recognition receptors and 
innate immune cells can subsequently initiate a cascading anti-fungal response, culminating in 
phagocytosis, removal of the fungal insult and down-regulation of inflammatory cytokine 
signalling10,11. In a healthy host these innate mechanisms ensure that fungal spores are cleared11. In 
a host with a pre-existing disorder, such as asthma, there is a risk that fungal exposure will lead to 
airway colonisation, and disorders such as Severe Asthma with Fungal Sensitisation (SAFS) or 
ABPA10,11. It has been suggested that fungal sensitisation and asthma severity may be related, and 
a temporal relationship between fungal exposure and clinical outcome has been shown2,12.  While 
interest remains in relation to Aspergillus colonisation, attention to other fungi is also of interest 
and a wider group of sensitisation to genera such as Candida and Penicillium exists and is 
encompassed within the diagnosis Allergic Bronchopulmonary Mycosis5. 
In this study, we sought to ascertain whether fungi, and in particular Aspergillus were present in 
the airways of asthmatics across the spectrum of disease severity and determine whether their 
presence was associated with airway and systemic cytokines, levels of control, disease severity or 
treatment with steroids. We additionally wished to determine whether or not systemic sensitisation 
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The study was approved by the Clinical Research Ethics Committee of the Cork Teaching 
Hospitals.  Sixty-nine patients with a history of asthma (either documented change in FEV1 
≥12%/200ml with bronchodilator or a positive inhalation challenge) were recruited through a 
dedicated asthma clinic in a tertiary referral centre. Patients with ABPA were excluded. Patients 
were scheduled for bronchoscopy, with spirometry, ACQ-7 and blood sampling performed on the 
day of bronchoscopy. Written informed consent was obtained from patients on the day of 
bronchoscopy. Spirometry was performed according to ATS/ERS guidelines13. The cohort was 
stratified by both severity [mild (GINA 1+2), moderate (GINA 3) and severe (GINA 4+5)] and 
asthma control (ACQ-7)14,15 (Table 1). Serum was assessed for total IgE and A.fumigatus specific 
IgE and plasma was assessed for cytokines. Patients underwent bronchoscopy according to 
standard guidelines16. Bronchoalveolar lavage (BAL) was obtained as a standardised 180ml 
(3X60ml) sample from either the right middle lobe or lingula as we have previously described17. 
Microscopy
A differential cell count was performed on BAL cytospin slides, stained with the Kwik-Diff kit 
(Thermo-Fisher) using light microscopy and Olympus DP software. Immune cell percentage 
counts were calculated and slides scored for fungal presence by 3 independent observers and 
microscopic observation of fungus was determined by size and presence of hyphae and/or spores. 
Samples received a positive or negative fungal score (0/1). A representative positive sample is 
shown in figure 1 B-C.
DNA extraction
To remove host cell DNA, BAL was centrifuged at 500g for 10 minutes, supernatant collected and 
DNA extraction performed. DNA extraction took place using a QIAamp UPC Pathogen Mini Kit 
(Qiagen, Manchester, UK) with DNA quantification performed using a NanoDrop 2000 
Spectophotometer (Fisher Scientific, Dublin, Ireland). 
Fungal quantitative PCR
Primers were designed and validated. qPCR was performed on extracted BAL DNA to determine 
presence of fungi and A. fumigatus using a total fungal primer (Fungi Quant)18 and an A. fumigatus 
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Platelia Aspergillus antigen (Galactomannan assay) 
Platelia Aspergillus antigen immunoenzymatic sandwich microplate assay (Bio-Rad, Dublin, 
Ireland) was performed on patient serum and BAL to determine presence/absence of Aspergillus 
galactomannan antigen. The optical density of each well was read at 450nm (reference filter 
620/630nm).
Cytokine measurement
Interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, IFN and tumour necrosis factor 
(TNF)-α were measured in plasma and BAL using an electro-chemiluminescence QuickPlex SQ 
120 imager from Meso Scale Discovery (Gaithersburg, MD, USA). 
Statistical analysis
Statistical analysis was performed using Graph Pad Prism Software 6. Appropriate tests such as T-
test, Spearman and Pearson Correlations were performed, with corrections for parametric/non-
parametric data. Results were considered statistically significant when P<0.05. 
Results
Patient demographics
Of the sixty-nine patients recruited, 61% were female. The cohort was stratified by asthma 
severity into 35% mild (GINA 1+2), 22% moderate (GINA 3), 43% severe (GINA 4+5) and level 
of control (ACQ-7) with 38% controlled (ACQ-7<1.5) and 62% uncontrolled (ACQ-7≥1.5). Seven 
patients (10%) were on maintenance oral steroids at the time of testing (7.5mg median; range 5-30 
mg daily). Ten asthmatics were newly diagnosed and ICS naïve at the time of sampling. Results 
and patient characteristics are summarised in table 1.
Serological detection of fungal sensitisation and presence
IgE levels were elevated in 38/69 (55%) of patients (mean 299.5; SD 512.1) (Figure S2). 6/69 
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for detection of Aspergillus galactomannan antigen afforded a positive result in one of the sixty-
nine patient’s serum. This was not related to elevated IgE. 
Fungal detection by microscopy 
BAL cell differential revealed macrophages to be the most dominant immune cell type with 
varying levels of neutrophils, eosinophils and lymphocytes present (Figure 1A). Fungal presence 
was detectable by microscopy in 48/69 (70%) of cytospins (Figure1B-C). Presence of fungi in 
cytospin slides correlated with increased neutrophils (P<0.05; rs = 0.275). There was no observed 
relationship between microscopic fungal presence in BAL and serum IgE levels or BAL 
eosinophils. 
Molecular detection of fungal presence
59/69 patients (86%) had detectable presence of fungi (Fungi Quant) and 32/69 (46%) had 
detectable A. fumigatus in BAL (Figure 2A). BAL A. fumigatus qPCR levels negatively correlated 
with macrophage counts (P<0.01; rs = -0.418) (Figure 2B). A. fumigatus did not correlate with 
BAL neutrophil or eosinophil counts. Total fungi, Fungi Quant qPCR, correlated with increased 
BAL neutrophils (P<0.05). Interestingly, patients who smoked had lower levels of A. fumigatus 
but not fungi by qPCR (P<0.05; rs=0.171). Severe asthmatic patients (GINA 4/5) also had lower 
levels of detectable fungi (P<0.05; rs=0.084) but asthma severity had no relationship with levels 
of detectable A. fumigatus. There was no significant difference in detection of fungi or A. 
fumigatus in patients on high or low dose inhaled corticosteroids (ICS) or on maintenance oral 
steroids. When grouped by allergic (total IgE>80 KU/L) and non-allergic asthma 34/38 allergic 
asthma patients had detectable fungi and 17/38 had detectable A. fumigatus by qPCR. For non-
allergic asthma patients 25/31 had detectable fungi and 15/31 had detectable A. fumigatus. When 
grouped by eosinophilic and non-eosinophilic asthma 21/23 patients with eosinophilia (peripheral 
eosinophil count > 0.3) had detectable fungi and 10/23 had detectable A. fumigatus by qPCR. In 
non-eosinophilic asthma patients 38/46 had detectable fungi and 22/46 had detectable A. fumigatus 
by qPCR. There were no statistical differences between detectable fungi or A. fumigatus between 
allergic and non-allergic asthma. There were no statistical differences between detectable fungi 
and eosinophilic or non-eosinophilic asthma, however there was a statistically significant 
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30 patients had detectable fungi by both qPCR assays (Fungi Quant and A. fumigatus) and 22 
patients had corresponding positive results for A. fumigatus detection by qPCR and detectable 
fungal presence by microscopy 20. 40 patients had corresponding positive total fungal qPCR and 
detectable fungi by microscopy of which 21 patients had fungi detectable by microscopy and both 
qPCR assays (Fungi Quant and A. fumigatus). As expected fungi other than A. fumigatus are 
detectable in BAL, however the identities of these were not investigated further in this study 
(Figure S3).
5 patients had a positive Galactomannan result for presence of Aspergillus in BAL. Only one 
patient was positive for A. fumigatus qPCR, microscopy, BAL Galactomannan and Fungi Quant 
qPCR. (Figure S5). FEV1 negatively correlated with BAL galactomannan (P<0.05).
Plasma and BAL cytokine levels correlate with BAL fungal presence  
Cytokines Interleukin (IL)-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, IFN and TNF-α were 
measured in plasma and BAL (Figure 3). BAL qPCR with the total fungi primer, Fungi Quant, 
correlated with plasma IL-4 (P<0.001), IL-6 (P<0.05) IL-10 (P<0.01) IL-13 (P<0.05), IL-17 
(P<0.01) and TNFα (P<0.001). A correlation between total fungi and IL-1β, IL-5, IL-8 and IFN-
 was not observed (Figure S6). Microscopic detection of fungi in BAL also correlated with 
plasma IL-4 (P<0.05), IL-6 (P<0.01) and TNFα (P<0.01). 
BAL Fungi qPCR correlated with increased BAL IL-4 (P<0.05), IL-6 (P<0.05), IL-10 (P<0.01), 
IL-13 (P< 0.05) and TNFα (P<0.05) but not IL-1β, IL-5, IL-8 and IL-17 (Figure S7). Microscopic 
detection of fungi in BAL correlated with BAL IL-4 (P<0.01) and IL-10 (P<0.01).
A. fumigatus positive BAL, by qPCR, correlated with increased plasma IL-6 (P<0.001) and 
increased BAL IL-6 (P< 0.01) and IL-13 (P<0.05) but not BAL and plasma IL-1β, IL-4, IL-5, IL-
8, IL-10, IL-17, TNFα or plasma IL-13 and IFNγ (Figure S8).
The presence of fungi by microscopy and qPCR also correlated with changes in BAL cell counts, 
particularly with increased neutrophils (P<0.05; rs=0.296). 
BAL eosinophil percentage counts correlated with plasma IL-5 (P<0.005; rs=0.349) and BAL IL-
5 (P<0.05; rs=0.263). Neutrophil cell percentage counts correlated with plasma IL-4 (P<0.05; rs=-
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with BAL IL-6 (P<0.01; rs=-0.296), IL-10 (P<0.01; rs=-0.302) and TNFα (P<0.05; rs=-0.250). 
Monocytes correlated with plasma IL-17 (P<0.001; rs=0.381), TNFα (P<0.01; rs=0.372) and IFNγ 
(P<0.005; rs=0.372) and BAL IL-4 (P<0.01; rs=0.320). FEV1 negatively correlated with BAL IL-
5 (P<0.005; rs=-0.352).
Discussion
Our study has demonstrated presence of fungi within the airways of adult asthmatic patients with 
varying asthma severity and levels of control. Microscopic and nucleic analysis revealed that 
fungi, including A.fumigatus, were detectable in BAL. Microscopy alone revealed spores and 
hyphae within 70% of the cohort and qPCR analysis demonstrated that 86% of patients have 
fungal presence within their BAL. Almost half (46%) of the cohort had detectable A.fumigatus in 
their airways. Despite the high frequency of fungi and specifically A. fumigatus, we were unable to 
find any association between its presence and measures of control, severity, or steroid use, in 
contrast to previous reports21. In fact, severe asthmatic patients had less detectable  fungi in 
comparison to mild and moderate GINA grouped patients but there was no relationship between 
severity and levels of A. fumigatus. Asthma severity was associated with BAL neutrophils, 
however the presence of A. fumigatus did not correlate with BAL neutrophil or eosinophils but 
was associated with reduced BAL macrophages. The detection of fungal DNA (Fungi Quant) in 
BAL did however correlate with BAL neutrophil counts. This observation of BAL fungal presence 
associated with BAL neutrophilia, is in keeping with other studies in which A. fumigatus alkaline 
protease 1 levels in sputum correlated with sputum neutrophilia but not eosinophil levels22.
Elevated IgE levels were observed in 38/69 patients suggesting that 55% of the cohort has atopic 
asthma. While qPCR revealed fungi in BAL of 86% and A. fumigatus in 46% of patients, serum 
antibody titres for A. fumigatus specific IgE were only positive in 9%. A. fumigatus IgE positivity 
did not indicate a A. fumigatus qPCR positive result in 3 patients (Figure S4). Antigen testing for 
fungi involves detection of specific antigen components present in the fungal cell wall which have 
been shed into blood or other body fluids. Several of these antigens have been utilised recently as 
an aid in detection of fungi, for example, galactomannan antigens in serum or BAL to diagnose 
invasive Aspergillus infection23. In our study, galactomannan was detectable in serum of 1 patient 
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methods, no patient tested positive for all parameters (Figure S4). Antigen testing has restrictions 
which must be considered when used to diagnose fungal infections. False positive serum 
Aspergillus galactomannan assays may exist in patients presenting with other fungal infections, in 
those taking β-lactam antibiotics or in presence of penicillium infections because of the possibility 
of cross-reactivity23. However, none of our patients were exacerbating or on antibiotics at the time 
of sample acquisition.
Nucleic analysis was revealed to be a more robust method of detecting presence of fungi and A. 
fumigatus within BAL of our asthmatic cohort. It was discovered that 21 patients tested positive 
for all criteria; total fungi by qPCR (Fungi Quant), A. fumigatus by qPCR and fungal detection by 
microscopy. 40 patients diplayed a positive total fungi qPCR result and fungal presence by 
microscopy, while 10 displayed fungal presence by qPCR alone. This suggests that while A. 
fumigatus is present within BAL of our asthmatics it is not the only fungal species present, as 
elucidated by our total fungi and microscopy results (Figure S3). 
The results suggest, at present, the best indicator of fungal and A. fumigatus presence in BAL is 
qPCR (Figure S3-S5). Previous studies have reported A. fumigatus detection in sputum was 
associated with IgE sensitisation, airway neutrophilia and reduction in lung function. This study 
utilised fungal culture of sputum. Furthermore, Aspergillus was cultured in 63% of IgE sensitised 
patients, but also 31% of non sensitised patients. In this study of 79 patients, 89% were classified 
as GINA 4/524. Our study included less severe asthmatics but higher numbers of mild and 
moderate asthmatics. 
The presence of A. fumigatus in BAL, by qPCR, negatively correlated with macrophage counts. 
Alveolar macrophages are responsible for uptake and removal of inhaled conidia25.  The ability of 
macrophages to kill Aspergillus species is dependent on LC3-associated phagocytosis via NADPH 
oxidase function. In human macrophages A. fumigatus has the ability to germinate in the late 
phagosome resulting in macrophage necrosis. Macrophages play a key role in protection of the 
host and their alteration or destruction can cause deleterious effects in the host11. We are uncertain 
as to whether the associated reduction in percentage BAL macrophages we observed is reflective 
of destruction by Aspergillus or simply a reciprocal decrease due to increase in neutrophils and 
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Cytokines, intracellular signalling proteins, target specific cells causing consequences such as cell 
mediated immunity and allergic responses26-28. It was generally believed disequilibrium between 
pro-inflammatory Th1 and anti-inflammatory Th2 groups plays a role in the pathogenesis of 
allergic airway responses. However regulatory T cells (Tregs) producing cytokines such as 
inhibitory IL-10 and IL-17 producing Th17 cells make elucidating the pathogenesis of allergic 
disorders more complex27-32.  Cytokines were chosen in order to investigate known cytokines of 
interest in asthma and to also examine the complex groups of Th1, Th2, Tregs and Th17 
representative cytokines. Within our cohort it was seen that presence of fungi within BAL, as 
detected by qPCR, correlated positively with levels of a number of cytokines.  Fungal presence 
within the lungs positively correlated with plasma IL-4, IL-6, IL-10, IL-13, IL-17 and  TNFα and 
BAL IL-4, IL-6, IL-10, IL-13 and TNFα. It is therefore plausible that presence of fungi within the 
lungs of these patients has triggered an immune response resulting in upregulation of these 
cytokines33-35. Our study focused on detection of fungi rather than specific viable culture. Further 
studies to culture specific fungal species may be attempted in the future, however there are many 
difficulties in culturing fungi in clinical laboratories. It has been documented that culture 
identification can be significantly affected by the starting volume of sample and qPCR has been 
observed to be the most sensitive method of detection36
It is notable within our cohort, that presence of A.fumigatus in BAL, as detected by qPCR, 
positively correlated with BAL IL-6 and IL-13 levels and plasma IL-6, suggesting a systemic 
response. 
Neutrophils are key players implicated in removal of fungal components within the lung through 
the use of phagocytic oxidative and non-oxidative mechanisms and through release of granules 
which mediate extracellular killing34. Patient BAL neutrophils correlated negatively with plasma 
IL-4 and TNFα and positively with BAL levels of the neutrophil chemoattractant IL-8 .Neutrophil 
presence also correlated with the presence of fungi by microscopy.
Macrophage cell percentage counts negatively correlated with BAL IL-10, IL-6 and TNF-α, and 
monocytes correlated positively with plasma IL-17, TNF-α, IFN-γ, and BAL IL-4.  It is of interest 
that in our cohort the percentage of macrophages negatively correlated with BAL IL-10. IL-10, an 
anti-inflammatory cytokine, regulates lung inflammation and  a decrease in IL-10 might be 
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As in previous studies we found BAL eosinophil levels correlated with plasma and BAL IL-5 
levels. IL-5 is essential for maturation of eosinophils in the bone marrow and subsequent release 
into the blood. Furthermore, IL-5 inhibition through monoclonal antibody therapy has 
demonstrated clinical effectiveness in treating patients with severe, eosinophilic asthma38. IL-17 
has been highlighted as a key component of fungal immunity35. It is known that pulmonary 
epithelial cells possess IL-17 receptors which induce antimicrobial peptide and chemokine 
production and resulting Th17 cell induction and neutrophil recruitment35. Members of our group 
have previously demonstrated ability of IL-17 to upregulate release of several cytokines and 
chemokines from primary bronchial epithelial cells but in particular those associated with 
neutrophilia39. In our current study, we observed that BAL fungal presence by qPCR correlated 
with plasma IL-17. Patient BAL monocyte precentage counts positively correlated with plasma 
IL-17.
It has been recently highlighted by Hernández-Santos et al. that ability of innate immune cells to 
kill fungi is dependent on presence of NF-κB mediated production of chemokines by pulmonary 
epithelia, which is IL-1R dependant. This chemokine cascade orchestrates Th17 derived IL-17A 
and GM-CSF signalling which are known to aid phagocytic destruction of fungi35. 
Our results have demonstrated through both rapid microscopy and qPCR methods, that fungi and 
to a lesser extent A. fumigatus are present in lower airways of a large proportion  of an adult  
asthmatic cohort regardless of their disease severity. Serological and antigen testing alone revealed 
a far lower level of positivity for Aspergillus. The presence of serum A. fumigatus specific IgE did 
not always predict presence of A. fumigatus by qPCR in patients BAL. Positive A. fumigatus-
specific IgE was not linked to disease severity or control. It is therefore possible that while there 
are detectable fungal and A. fumigatus communities within the lungs of our cohort, perhaps this 
presence is not always provoking an active immune response. Furthermore, positivity for  serum 
A. fumigatus specific IgE was not associated with a reduction in FEV1. Our findings appear to 
differ from previously published results suggesting that asthma patients sensitised to Aspergillus 
had lower FEV124.  
FEV1 negatively correlated with BAL IL-5 and BAL galactomannan, however it should be noted 
that only 5/69 patients showed BAL galactomannan positivity. Of the 5 patients who tested  
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BAL Galactomannan may relate to airway fungal presence but not necessarily presence of  
A.fumigatus. 
One of the weaknesses of the current study is the lack of control group which we aim to address in 
future work. This considerable undertaking is suggested by the results of our present study and 
will require a careful ethics case to be made, that will allows a generally safe but invasive 
procedure in volunteers. A strength of our study however was that it did include patients of all 
asthma severity and indeed patients on maintenance oral steroids and patients newly diagnosed 
and yet to receive any asthma-directed therapy. The decision to exclude patients with ABPA was 
made in an effort to specifically interrogate the current definition of SAFS which excludes this 
group. Further studies aimed at addressing this group are planned for the future.  Fungal 
sensitisation is the sudden cutaneous hyperreactivity to fungal antigen or elevation of fungal 
specific IgE40. SAFS is a subphenotype of severe asthma41. Fungi are associated with severe 
asthma through fungal spore inhalation, sensitisation or the causation of Allergic 
Bronchopulmonary Mycosis40.. Previous studies revealed numerous fungal species can cause 
sensitisation in asthmatics, however it is not yet known which is implicated to the greatest degree 
in SAFS and if it is prevalent within other subgroups of asthma40. It would therefore be of interest 
to investigate this further in order to interrogate the current definition of SAFS. 
Further studies are required to assess whether or not Aspergillus within the asthmatic airway has a 
pathological role in the disease. Our study has shown an almost ubiquitous presence of fungi 
within the asthmatic airway regardless of disease severity, treatment taken and presence of 
systemic sensitisation. It has become apparent from this study that other fungal species are present 
within the lungs of our asthmatic cohort. Whether or not these fungi play a pathophysiological role 










This article is protected by copyright. All rights reserved
References
1. Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-
BIOPRED adult severe asthma cohort. The European respiratory journal. 2015;46(5):1308-1321.
2. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. The link between fungi and 
severe asthma: a summary of the evidence. The European respiratory journal. 2006;27(3):615-
626.
3. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal 
treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial 
(FAST) study. Am J Respir Crit Care Med. 2009;179(1):11-18.
4. Agbetile J, Bourne M, Fairs A, et al. Effectiveness of voriconazole in the treatment of Aspergillus 
fumigatus-associated asthma (EVITA3 study). The Journal of allergy and clinical immunology. 
2014;134(1):33-39.
5. Rick EM, Woolnough K, Pashley CH, Wardlaw AJ. Allergic Fungal Airway Disease. Journal of 
investigational allergology & clinical immunology. 2016;26(6):344-354.
6. Underhill DM, Iliev ID. The mycobiota: interactions between commensal fungi and the host 
immune system. Nat Rev Immunol. 2014;14:405.
7. Gauthier GM. Dimorphism in Fungal Pathogens of Mammals, Plants, and Insects. PLoS Pathogens. 
2015;11(2):e1004608.
8. Hohl TM, Feldmesser M. Aspergillus fumigatus: principles of pathogenesis and host defense. 
Eukaryotic cell. 2007;6(11):1953-1963.
9. Kwon-Chung KJ, Sugui JA. Aspergillus fumigatus—What Makes the Species a Ubiquitous Human 
Fungal Pathogen? PLOS Pathogens. 2013;9(12):e1003743.
10. Kousha M, Tadi R, Soubani AO. Pulmonary aspergillosis: a clinical review. European Respiratory 
Review. 2011;20(121):156-174.
11. van de Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latge JP. Aspergillus fumigatus 
morphology and dynamic host interactions. Nature reviews Microbiology. 2017;15(11):661-674.
12. Targonski PV, Persky VW, Ramekrishnan V. Effect of environmental molds on risk of death from 
asthma during the pollen season. The Journal of allergy and clinical immunology. 1995;95(5 Pt 
1):955-961.
13. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. The European respiratory 
journal. 2005;26(2):319-338.









This article is protected by copyright. All rights reserved
15. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a 
questionnaire to measure asthma control. The European respiratory journal. 1999;14(4):902-907.
16. Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible 
bronchoscopy in adults: accredited by NICE. Thorax. 2013;68 Suppl 1:i1-i44.
17. Hunt EB, Ward C, Power S, et al. The Potential Role of Aspiration in the Asthmatic Airway. Chest. 
2017;151(6):1272-1278.
18. Liu CM, Kachur S, Dwan MG, et al. FungiQuant: A broad-coverage fungal quantitative real-time 
PCR assay. BMC Microbiology. 2012;12(1):255.
19. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C, et al. Value of serial quantification of fungal DNA by 
a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with 
febrile neutropenia. J Clin Microbiol. 2009;47(2):379-384.
20. Oliveros JC. Venny. An interactive tool for comparing lists with Venn's diagrams. 2007-2015.
21. Fraczek MG, Chishimba L, Niven RM, et al. Corticosteroid treatment is associated with increased 
filamentous fungal burden in allergic fungal disease. The Journal of allergy and clinical 
immunology. 2018;142(2):407-414.
22. Basu T, Seyedmousavi S, Sugui JA, et al. Aspergillus fumigatus alkaline protease 1 (Alp1/Asp f13) in 
the airways correlates with asthma severity. The Journal of allergy and clinical immunology. 
2018;141(1):423-425.e427.
23. Limper AH. The Changing Spectrum of Fungal Infections In Pulmonary and Critical Care Practice. 
Proceedings of the American Thoracic Society. 2010;7(3):163-168.
24. Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with 
reduced lung function in asthma. Am J Respir Crit Care Med. 2010;182(11):1362-1368.
25. Segal BH. Role of macrophages in host defense against aspergillosis and strategies for immune 
augmentation. The oncologist. 2007;12 Suppl 2:7-13.
26. Chung KF, Barnes PJ. Cytokines in asthma. Thorax. 1999;54(9):825-857.
27. Berger A. Th1 and Th2 responses: what are they? BMJ. 2000;321(7258):424.
28. Zhang J-M, An J. Cytokines, Inflammation and Pain. International anesthesiology clinics. 
2007;45(2):27-37.
29. Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 cells: new players in asthma 
pathogenesis. Allergy. 2011;66(8):989-998.










This article is protected by copyright. All rights reserved
31. Maes T, Joos GF, Brusselle GG. Targeting Interleukin-4 in Asthma: Lost in Translation? American 
Journal of Respiratory Cell and Molecular Biology. 2012;47(3):261-270.
32. Lambrecht BN, Hammad H, Fahy JV. The Cytokines of Asthma. Immunity. 2019;50(4):975-991.
33. Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117(4):1162-1172.
34. Becker KL, Ifrim DC, Quintin J, Netea MG, van de Veerdonk FL. Antifungal innate immunity: 
recognition and inflammatory networks. Seminars in immunopathology. 2015;37(2):107-116.
35. Hernández-Santos N, Wiesner DL, Fites JS, et al. Lung Epithelial Cells Coordinate Innate 
Lymphocytes and Immunity against Pulmonary Fungal Infection. Cell Host & Microbe.23(4):511-
522.e515.
36. Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD. Volume dependency 
for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus 
quantitative PCR. Mycoses. 2014;57(2):69-78.
37. Bordon J, Aliberti S, Fernandez-Botran R, et al. Understanding the roles of cytokines and 
neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory 
response in pneumonia. International Journal of Infectious Diseases. 2013;17(2):e76-e83.
38. Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW. Th2 cytokines and asthma — The 
role of interleukin-5 in allergic eosinophilic disease. Respiratory Research. 2001;2(2):71-79.
39. Murphy DM, Forrest IA, Corris PA, et al. Simvastatin attenuates release of neutrophilic and 
remodeling factors from primary bronchial epithelial cells derived from stable lung transplant 
recipients. American journal of physiology Lung cellular and molecular physiology. 
2008;294(3):L592-599.
40. Agarwal R, Gupta D. Severe asthma and fungi: current evidence. Medical Mycology. 
2011;49(Supplement_1):S150-S157.
41. Licari A, Brambilla I, Marseglia A, De Filippo M, Paganelli V, Marseglia GL. Difficult vs. Severe 











This article is protected by copyright. All rights reserved
Table 1: Patient demographics broken into groupings of mild, moderate and severe asthma as 
defined by GINA groupings Mild (GINA 1+2), Moderate (GINA 3) and Severe (GINA 4+5).
Mild (GINA 1-2) Moderate (GINA 3) Severe (GINA 4-5)
Patients n=69 (%) 24 (35%) 15 (22%) 30 (43%)
Male 11 (46%) 5   (33%) 11 (37%)
Female 13 (54%) 10 (67%) 19 (63%)
Smoker Current 2 1 4
Ex- 17 2 9
Never 15 12 17
IgE (KU/L) [Mean (SD)] [354 (654.1)] [178 (252.3)] [317 (484.1)]
A. fumigatus IgE Positive 2 1 3
ACQ-7  † [Mean (SD)] (1 (0.6)] [2 (1.0)] [3 (1.1)]
FEV-1 (Percent Predicted) ‡ [Mean (SD)] [86 (13.7)] [88 (21.7)] [66 (22.3)]
FeNO (ppb) § [Mean (SD)] [25 (24.6)] [20 (14.0)] [17 (25.3)]
BMI (kg/m2) ¶ [Mean (SD)] [26 (4.5)] [29 (6.8)] [31 (6.7)]
BAL Galactomannan Positive 3 0 2
Serum Galactomannan Positive 0 0 1
BAL Fungal Microscopy Positive 18 12 18
BAL Total Fungi  (Cp) Positive 20 14 25
[Mean (SD)] [34 (2.2)] [34 (2.6)] [36 (2.2)]
BAL A. fumigatus (Cp) Positive 13 7 12
[Mean (SD)] [34 (3.4)] [36 (1.4)] [34 (2.6)]
BAL Monocyte % count [Mean (SD)] [8 (7.6)] [6 (8.3)] [4 (4.6)]
BAL Macrophage % count [Mean (SD)] [80 (10.20)] [62 (27.4)] [75 (20.1)]
BAL Lymphocyte % count [Mean (SD)] [7 (5.1)] [9 (11.4)] [9 (10.6)]
BAL Eosinophil % count [Mean (SD)] [2 (2.1)] [3 (5.5)] [3 (8.2)]
BAL Neutrophil % count [Mean (SD)] [3 (7.4)] [14 (20.7)] [5 (6.9)]
BAL IL-4 (pg/ml) [Mean (SD)] [0.5 (1.9)] [0.1 (0.1)] [1 (1.9)]
BAL IL-5 (pg/ml) [Mean (SD)] [0.2 (0.4)] [0.7 (2.4)] [2 (7.4)]
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 Note † ACQ-7, Asthma Control Questionnaire; ‡ FEV-1, Forced Expiratory Volume in the first 
second; § FeNO, Fractional exhaled Nitric Oxide; ¶ BMI, Body Mass Index. 
Table 1 Patient Demographics. Breakdown of patient demographics based on patient groupings 
of mild, moderate and severe asthmatics as defined by GINA groupings of GINA 1+2 = mild, 
GINA 3 = moderate and GINA 4+5 = severe with our results for each level of asthma severity 
shown.
Figure Legends
Figure 1 Microscopic evidence of fungal presence in asthmatic patient bronchoalveolar 
lavage (BAL). (A) BAL immune cell differential counts revealed macrophages to be the most 
dominant immune cell type present with varying levels of neutrophils and eosinophils present 
within the patient BAL. (B-C) Representative microscope images of patient BAL fluid stained 
with a commercial Kwik-Diff stain displaying fungal presence. Fungal hyphae (B) and conidia (C) 
detected at 40x. n=69
BAL IL-8 (pg/ml) [Mean (SD)] [397 (843.2)] [740 (1846)] [236 (318.1)]
BAL IL-10 (pg/ml) [Mean (SD)] [0.7 (2.3)] [0.2 (0.3)] [1 (1.4)]
BAL IL-13 (pg/ml) [Mean (SD)] [4 (10.7)] [3 (1.7)] [6 (6.9)]
BAL IL-1β(pg/ml) [Mean (SD)] [8 (30.8)] [5 (16.2)] [5 (10.1)]
BAL TNF-α(pg/ml) [Mean (SD)] [1 (2.4)] [0.4 (0.5)] [2 (2.3)]
Plasma IL-4 (pg/ml) [Mean (SD)] [0.6 (1.6)] [0.2 (0.1)] [3 (5.1)]
Plasma IL-5 (pg/ml) [Mean (SD)] [0.6 (0.8)] [0.8 (1.6)] [0.9 (2.0)]
Plasma IL-6 (pg/ml) [Mean (SD)] [1 (1.8)] [0.8 (0.9)] [3 (4.3)]
Plasma IL-8 (pg/ml) [Mean (SD)] [5 (2.4)] [8 (14.1)] [13 (28.1)]
Plasma IL-10 (pg/ml) [Mean (SD)] [1 (3.0)] [0.8 (1.2)] [5(10.0)]
Plasma IL-13 (pg/ml) [Mean (SD)] [8 (16.6)] [5 (4.3)] [25 (35.9)]
Plasma IL-1β(pg/ml) [Mean (SD)] [0.6 (3.0)] [0.1 (0.2)] [1 (2.3)]
Plasma TNF-α(pg/ml) [Mean (SD)] [5 (11.8)] [2 (1.3)] [16 (24.9)]
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Figure 2 qPCR detection of Fungi in asthmatic BAL. (A) qPCR was performed on the extracted 
BAL DNA using the Fungi Quant, and Aspergillus fumigatus ITS specific primer; 59 patients 
(86%) had detectable fungi within their lungs and 32 patients (46%) had detectable Aspergillus 
fumigatus within their lungs. (B) BAL Aspergillus fumigatus qPCR levels were seen to correlate 
with macrophage immune cell percentage count levels (P<0.05; Spearman r = -0.4176). n=69
Figure 3 Cytokine Levels in the Patient Plasma and BAL Measurement of secreted human 
cytokines interleukin- 1β (IL-1β), IL-4, IL-5, IL-6, IL-8, IL-10, IL-13, IL-17, IFN and tumour 
necrosis factor-α (TNF-α) were measured in patient serum and BAL using an electro-
chemiluminescence QuickPlex SQ 120 imager from Meso Scale Discovery (Gaithersburg, MD, 
USA) where antibodies labelled with SULFO-TAG™ reagents emitted light upon electrochemical 
stimulation. Cytokines were detectable above the lower limit of detection set by the assay 
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